Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease

Albino Carrizzo1, Alba Di Pardo1, Vittorio Maglione1, Antonio Damato1, Enrico Amico1, Luigi Formisano2, Carmine Vecchione1,3, Ferdinando Squitieri1*

1 IRCCS Neuromed, Pozzilli (IS), Italy, 2 Department of Science and Technology, University of Sannio, Benevento, Italy, 3 Department of Medicine and Surgery, University of Salerno, Salerno, Italy

Abstract

Nitric oxide (NO) is a biologically active inorganic molecule involved in the regulation of many physiological processes, such as control of blood flow, platelet adhesion, endocrine function, neurotransmission and neuromodulation. In the present study, for the first time, we investigated the modulation of NO signaling in platelets of HD patients. We recruited 55 patients with manifest HD and 28 gender- and age-matched healthy controls. Our data demonstrated that NO-mediated vasorelaxation, when evoked by supernatant from insulin-stimulated HD platelets, gradually worsens along disease course. The defective vasorelaxation seems to stem from a faulty release of NO from platelets of HD patients and, it is associated with impairment of eNOS phosphorylation (Ser1177) and activity. This study provides important insights about NO metabolism in HD and raises the hypothesis that the decrease of NO in platelets of HD individuals could be a good tool for monitoring advanced stages of the disease.

Citation: Carrizzo A, Di Pardo A, Maglione V, Damato A, Amico E, et al. (2014) Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease. PLoS ONE 9(2): e89745. doi:10.1371/journal.pone.0089745

Editor: Cristoforo Scavone, Universidade de São Paulo, Brazil

Received: August 12, 2013; Accepted: January 23, 2014; Published: February 25, 2014

Copyright: © 2014 Carrizzo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ferdinando.squitieri@lirh.it (FS); cvvecchione@unisa.it (CV)

These authors contributed equally to this work.

Introduction

Huntington disease (HD), a dominantly transmitted neurodegenerative disorder, is characterized by the progressive striatal and cortical neurodegeneration associated with motor, cognitive and behavioral disturbances [1]. The disease-causing mutation is an expansion of a CAG trinucleotide repeat (>36 repeats) encoding a polyglutamine (polyQ) stretch in N-terminal region of huntingtin (Htt), a ubiquitous protein whose function is still unclear. Elongated polyQ stretch endows mutant Htt (mHtt) with toxic properties and results in the development of a broad array of cell dysfunctions [2]. Although the disease has traditionally been described as a disorder purely of the brain, emerging evidence indicates that abnormalities outside the central nervous system (CNS) are commonly found in HD [3]. However, whether a correlation exists between central pathology and peripheral defects is still poorly understood.

Mutant Htt has been widely described to be expressed either in central or in peripheral tissues and to exert its toxic effect in both neuronal and non-neuronal cells with similar mechanisms [4].

Previous studies highlighted the ability of mHtt to interfere with a number of molecular mechanisms in peripheral tissues, which have been suggested to virtually reflect central dysfunctions in HD and potentially useful to better understand some genetic and biochemical aspects of the disease [5,6].

Among all the several dysfunctions, the dysregulation of nitric oxide (NO)/NO synthase (NOS) pathway is suggested to potentially represent a critical contributor to HD pathology [7]. NO, known as an important signaling molecule, normally acts in many tissues and regulates a diverse range of physiological and cellular processes such as control of blood flow, platelet adhesion, neurotransmission and neuromodulation [8]. Production of NO is mediated by different NOS isoforms in both CNS and peripheral tissues [9]. Human platelets, that normally express the endothelial form of NOS (eNOS), whose activity is regulated by phosphorylation at different Serine/Threonine residues [10], represent an important source of peripheral NO. Under pathological condition, production of NO can be either protective or toxic, depending on the stage of the disease, the isoforms of NOS involved and, the initial pathological event [7]. To date, many are the studies that described NO as a potential key mediator of neurodegeneration [11,12].

NO dysfunction in CNS has been previously demonstrated to be involved in different processes leading to progressive striatal damage and to abnormal cerebral blood flow (CBF) in both HD experimental models and patients [7,13]. However, there is no actual evidence proving NO abnormalities in peripheral blood cells.

In this study, we carried out experiments on platelets, which represent a validated peripheral model for testing potential impairment of NO regulation, obtained from patients with manifest HD. Our data highlighted defective NO metabolism in the advanced stages of HD and, for the first time, revealed a possible stage-dependent dysregulation of peripheral eNOS signaling in the disease.
Methods

Subjects
A total of 55 HD patients (11 stage I, 17 stage II, 16 stage III and 11 stage IV), and 28 gender- and age-matched healthy controls were recruited in this study. Control group was divided in two subgroups consisting of a younger control group with a mean age of 43.8±7.4 and an older control group with a mean age of 59.7±3.4 in order to match them with early (stage I and II) and late (stage III and IV) HD patients, respectively. Classification of control subjects in young and old groups has been performed in a manner similar to that described previously [14]. Subjects’ demographic, clinical and genetic characteristics of both controls and HD patients are reported in Table 1. All the subjects with suspect of cardiovascular, psychiatric or neurodegenerative disorders other than HD, were excluded from this study. Most patients were taking benzodiazepines; some of the patients in stage III-IV were receiving low doses of atypical neuroleptics (olanzapine, 2.5–10 mg; risperidone, 1–3 mg or tetrabenazine, 12.5–25 mg). None of the patients were taking medication for any cardiovascular diseases. Clinical examinations were conducted using the Unified Huntington’s Disease Rating Scale (UHDRS) to measure motor, cognitive, behavioral and general function (Huntington Study Group, 1996) [15]. The disease stage was estimated.

Ethics Statement
All HD patients revealed a CAG repeat expansion mutation, and all of them, as well as control individuals, were requested to sign an informed consent before study recruitment. All human experiments were performed in accordance with the Declaration of Helsinki and after approval from the local Ethical Committee of Istituto Neurologico Mediterraneo IRCCS Neuromed [17].

Platelet isolation
Twenty-five millilitres of blood were collected into acid citrate dextrose (ACD: 85 mMol/L sodium citrate, 65 mMol/L citric acid, and 125 mMol/L dextrose; 2.5 ml ACD: 25 ml of blood) and dextrose (ACD: 85 mMol/L sodium citrate, 65 mMol/L citric acid, and 125 mMol/L dextrose; 2,5 ml ACD:25 ml of blood) and gassed with 95% air, and 5% CO2 for 7 minutes, and resuspended in Tyrode’s solution (132 mMol/L NaCl, 4 mMol/L KCl, 1.6 mMol/L CaCl2, 0.98 mMol/L MgCl2, 23.8 mMol/L NaHCO3, 0.36 mMol/L NaH2PO4, 10 mMol/L glucose, 0.05 mMol/L Ca-Tritirplex, and gassed with 95% O2, 5% CO2 and pH 7.4 at 37°C). After a further centrifugation step (900 g, 4 minutes), washed platelets were resuspended in the same solution, allowed to equilibrate for 10 minutes at 37°C and then stimulated with insulin (10 μM/L) for 10 minutes. Some experiments were performed in platelet pre-treated with Nω-nitro-L-arginine methyl ester (L-NAME) (300 μM/L, 30 minutes) or with 1 mM/L 4-hydroxytempol (TEMPO), a membrane-permeable superoxide dismutase mimetic, for 30 minutes. After stimulation, the platelet suspension was centrifuged for 2 minutes at 900 g and, increasing doses of supernatant (0.1-0.2-0.4-0.8 ml) was added to phenylephrine-precontracted arteries mounted in an organ chamber (final volume, 15 ml). Total number and purity of platelets for each preparation was assessed by flow cytometry. Total protein from each preparation was also determined. Similar number of platelets (186±15×10⁶/mL) between controls and HD patients was estimated.

Isolated vessel studies
Studies of vascular reactivity were performed on isolated vessels from C57BL6/N mice. Four ring segments (3 mm width) of thoracic aorta from each mouse were mounted between stainless steel triangles in a water-jacketed organ bath (37°C) for measurement of tension development as previously described [18,19]. Preliminary experiments demonstrated that the optimal resting tension for development of active contraction was 1 g. Vessels were gradually stretched over one-hour period to this tension. The presence of functional endothelium and smooth muscle layer were assessed in all preparations by the ability respectively of acetylcholine and nitroglycerin (10⁻⁶ to 10⁻⁴ mol/L) to induce the relaxation of vessels precontracted with phenylephrine (10⁻⁶ to 10⁻⁴ mol/L) to obtain a similar level of precontraction in each ring (80% of initial KCl-induced contraction). Responses to vasoconstrictors were examined at this resting tension and related to maximal vasoconstriction elicited by depolarization with 80 mMol/L KCl. Responses to vasodilator supernatants obtained from stimulation of platelets were examined after achieving a preconstricted tone with increasing doses of phenylephrine (10⁻⁶ to 10⁻⁴ mol/L) to obtain a similar level of precontraction in each ring (80% of initial KCl-induced contraction).

Immunoblotting
After isolation, platelets were solubilized in lysis buffer containing: 20 mMol/L Tris-HCl, 150 mMol/L NaCl, 20 mMol/L NaF, 2 mMol/L sodium orthovanadate, 1% Nonidet, 100 μg/ml leupeptin, 100 μg/ml aprotinin, and 1 mMol/L phenylmethylsulfonyl fluoride. Then, samples were left on ice for

Table 1. Demographic and clinical data of healthy controls and HD patients.

| Subjects | Young Controls | Old Controls | Huntington disease stages | Early | Late |
|----------|---------------|-------------|--------------------------|-------|------|
| Male/Female | 9/10 | 5/4 | I | 11 | 9/8 |
| Male/Female | 9/10 | 5/4 | II | 17 | 9/6 |
| Age (years) | 43.8±7.4 | 59.7±3.4 | III | 54.2±11.2 | 5/6 |
| TFC (score) | 11.5±1 | 7.5±0.7 | IV | 1.6±0.5 |
| CAG repeats | 43.2±1.5 | 45.6±6.3 | | 44.7±3.4 |

Values are given as mean ± s.d.; TFC: Total Functional Capacity, score 13-0. doi:10.1371/journal.pone.0089745.t001
30 minutes and centrifuged at 10621 g for 20 minutes, and the supernatants were used to perform immunoblot analysis. Total protein levels were determined using the Bradford method. 50 μg proteins were resolved on 8% SDS-PAGE, transferred to a nitrocellulose membrane as previously described [20] and immunoblotted with anti-phospho-eNOS S1177 (Cell Signaling, rabbit polyclonal antibody 1:800); anti-total-eNOS (Cell Signaling, mouse mAb 1:1000) and β-actin (Cell Signaling, mouse mAb 1:2000). HRP-conjugated secondary antibodies were used at 1:3000 dilution (Bio-Rad Laboratories). Protein bands were detected by ECL Prime (Amersham Biosciences) and quantitated with Quantity One software (Bio-Rad Laboratories).

Determination of platelet Nitric Oxide Synthase activity

Endothelial NOS activity was determined on platelet lysates according to the protocol published by Radomski et al. (1993) [21]. Briefly, the enzymatic activity was determined by measuring the conversion of L-[14C]arginine to L-[14C]citrulline. The dependence of L-arginine conversion on Ca2+-dependent (constitutive) NOS was confirmed in presence of ethyleneglycol bis-(2-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA), and of N(G)-mono-methyl-L-arginine (L-NMMA), an inhibitor of this enzyme. The isoform specificity of this analysis is demonstrated through the use of the calcium chelator EGTA, which allows us to fractionate calcium-independent (iNOS) activity versus total NOS activity (inhibited by L-NMMA). Assay sensitivity has been shown to be just less than 1 pmol/min/mg protein for the detection of L-[14C]arginine.

Measurement of NO production in platelets

Isolated platelets were centrifuged at 1500 g for 10 minutes and platelets were washed twice with a 6:1 mixture of Hank’s balanced salt solution (HBSS) and ACD. Platelet suspensions (100 μL) were incubated with 1 μmol/L diaminodifluoroscein diacetate (DAF-FM DA), a photo-stable NO fluorescent indicator, in HBSS at room temperature for 30 minutes and stimulated with 10 μmol/L insulin. After incubation, fluorescence emission spectra were recorded in a 495-515 nm range in a quartz cuvette as described elsewhere [22].

Statistical analysis

One-way ANOVA followed by Turkey post-test was used to analyze protein levels, eNOS activity and DAF fluorescence measurement. Two-way ANOVA followed by Bonferroni post-test was used for the analysis of vascular reactivity studies in HD patients and controls. All data are presented as mean ± SD, except in the dose-response curve studies in which are expressed as mean ± SEM. A “p” value of less than 0.05 was considered statistically significant. F value (F) and degree of freedom (df) were also reported for each experiment. All statistical analyses were conducted with Prism statistical software.

Results

Vasorelaxation evoked by supernatant from insulin-stimulated platelets gradually alters along disease course

The supernatant from insulin-stimulated human platelets evoked a rapid dose-dependent relaxation of mice aorta rings and was abolished by NOS inhibitor, L-NAME (Figure 1A). Clearly demonstrating the involvement of NO signalling in supernatant vascular action. Interestingly, our data demonstrate that the vasorelaxant effect, evoked from platelet supernatants, was markedly reduced in late stage HD patients when compared to either early HD patients or control subjects (Figure 1B). No
differences were observed between early HD patients and age-matched control individuals (Figure 1B). Vasorelaxation did not differ between the two control groups, excluding, therefore, any possible aging process-related effects (Figure S1 in File S1).

Next, to elucidate the putative cause of aberrant NO pathway, the potential implication of oxidative stress was explored by pre-incubating platelets from late stage HD patients with the antioxidant agent, 4-hydroxytempo. Our data indicate that the compound failed to improve the supernatant vascular effect observed in late HD patients (Figure 1C), excluding the involvement of oxidative stress in such dysfunction.

eNOS-phosphorylation is impaired in HD
To elucidate whether HD-derived platelet-mediated impaired vasorelaxation due to dysregulation of eNOS pathway, phosphorylation state at its serine residue 1177, was determined by biochemical studies. Levels of eNOS phosphorylation gradually decreased from stage II up stage IV HD patients in which phosphorylation signal was merely detectable (Figure 2A). eNOS phosphorylation in late stage HD patients was significantly reduced when compared with either stage I HD patients or control subjects. No significant difference was observed between early stage HD patients and healthy controls (Figure 2A). Conversely, eNOS expression did not change among all the groups (Figure 2A). In addition, no changes in the levels of β-actin were observed between HD patients and healthy controls.

Furthermore, in order to clarify whether reduction of eNOS phosphorylation was associated with a defective eNOS activity along HD course, citrulline assay, the standard eNOS activity assay, was performed in platelets from different stated HD patients and healthy controls. Coherently with changes of eNOS phosphorylation, enzyme activity was found to be significantly decreased in patients with advanced HD compared to early HD patients and/or to controls subjects (Figure 2B).

NO is reduced in platelets from late stage HD patients
To test whether impaired vasorelaxant response, evoked by HD-derived platelet response, was attributable to abnormal NO production, platelet-derived NO from HD patients at different stage of the disease was quantitatively determined by DAF-FM DA. Consistent with decrease of both eNOS phosphorylation and activity (Figure 2A and B), NO release was markedly reduced in patients with advanced HD compared to early stage patients as well as to control subjects (Figure 3). No differences were found between early stage patients and control individuals (Figure 3).

Discussion
Several studies highlighted peripheral abnormalities in HD and arise the hypothesis that the disease may be associated with a number of pathological changes outside the brain. A common finding across numerous studies is that peripheral cells (circulating blood lymphocytes, monocytes and platelets) represent good candidates for biochemical studies [5,23,24], as well as for searching potential peripheral biomarkers that correlate with the onset and/or the progression of the disease [6,24].

It has been previously described an altered homeostasis of human platelets in HD [25,26] and an increased density of Adenosine A2a receptor, a protein G-coupled receptor implicated in the regulation of different biochemical processes including the release of NO, in both CNS of transgenic HD mice [13,27] and blood platelets of patients [5,6]. However, whether platelets dysfunction contributes to HD pathogenesis, or is an epiphhenomenon, remains unclear.

In this study we further examined the role of platelets in HD and postulate that the impairment of NO signaling in the peripheral district of patients might contribute to the pathology. In particular, we found that NO-mediated vasorelaxation, evoked by supernatant from HD-derived insulin-stimulated platelets was impaired in advanced HD. We also demonstrated stage-dependent changes of eNOS phosphorylation at serine residue (1177) associated with reduced eNOS activity and NO release in platelets from late stage HD patients. Importantly, as shown in Figure 1 and in Figure S1 in File S1, our results appear to be specifically related to HD pathology and not depending on aging process.

Interestingly, it has been previously shown that NO is produced in human platelets and that changes in intra-platelet NO production have important physiological and pathophysiological implications. The role of NO and its catalyzing enzyme, NOS, in neurodegenerative disease has been increasingly investigated over the past decade [27,28]. However little is known about the role of NO in HD.

NO plays an important role in the modulation of the vascular tone. It exerts vasorelaxant action and favors antiplatelet effects limiting thrombotic events [29]. Impaired NO signaling in patients might support the high incidence of cardiovascular complications, which represent one of the leading causes of death in HD [30,31]. Additionally, we observed that the progressive impairment of NO signaling along HD course seems not to depend exclusively on excessive oxidative stress. It has been previously reported that the effective half-life of NO and the vasorelaxation of aortic rings by NO is enhanced by a reduction in the concentration of superoxide radicals with superoxide dismutase (SOD) [32]. In our study, the administration of the antioxidant agent, TEMPOL, that mimics the action of SOD, did not rescue the altered vasorelaxation observed in the late stage HD patients. This result, therefore, allows us to suppose that superoxide radicals are not implicated in the impaired NO vascular action in patients with advanced HD. Interestingly, in support of this hypothesis, we found impaired activity of endothelial NOS enzyme in late stage HD patients.

Although the molecular mechanisms underlying the regulation of platelets eNOS activation and NO production are likely to be complex and will need to be further explored, we hypothesized that mHtt could affect eNOS phosphorylation through its interaction with a number of molecular targets including huntingtin-associated protein (HAP-1), CREB binding protein (CBP) and protein kinase B (AKT) [33], that have been previously described to interfere with eNOS signaling [28]. Reduction of eNOS expression and decreased NO levels in platelets from HD patients, could virtually reflect central defects and potentially clarify the molecular basis of cerebral hypoperfusion previously described in HD patients [34]. Although the clinical significance of altered eNOS/NO signal pathway is not yet elucidated, it is tempting to speculate that such impairment may be an important determinant that influences disease progression in HD.

In summary, our data indicate a gradual dysregulation of eNOS pathway in HD-derived platelets, which could represent a valuable
tool for determining a possible link between peripheral district and CNS. To our knowledge this is the first biological evidence of such peripheral dysregulation in HD. We believe that changes of peripheral eNOS/NO pathway during HD course could represent a potential indicator of disease severity, useful to monitor the advanced HD stages of HD. The biological characterization of late stages of HD may open new insights to therapy of advanced, untreated patients.

**Supporting Information**

File S1

(DOCX)

**Acknowledgments**

We are grateful to all patients for contributing to our work and to Lega Italiana Ricerca Huntington e malattie correlate (LIRH) onlus. Also, we thank Mariateresa Ambrosio and all the laboratory assistants for technical support and fruitful discussion. Vittorio Maglione is supported by a Marie Curie International Incoming Fellowship (IF, grant n° 300197) within the 7th European Community Framework Programme.
Author Contributions
Conceived and designed the experiments: AC ADP VM CV FS. Performed the experiments: AC AD. Analyzed the data: AC ADP VM CV FS. Wrote the paper: AC ADP VM CV FS. Provided technical assistance: EA. Performed the experiments for the determination of NOS activity: LF. Read and approved the final manuscript: AC ADP VM AD EA LF CV FS.

References
1. Roos RA (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5: 40.  
2. Sugars KL, Rabinstein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19: 253–258.  
3. van der Burg JM, Bjorkquist M, Brandun P (2009) Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 8: 765–774.  
4. Sassone C, Ciligi G, Califani G, Shiota V, Giannina A (2009) Huntington’s disease: the current state of research with peripheral tissues. Exp Neurol 219: 385–397.  
5. Maglione V, Giallonardo P, Cannella M, Martino T, Frati L, et al. (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington’s disease. Ann J Med Genet B Neuropsychiatr Genet 139B: 101–105.  
6. Maglione V, Cannella M, Martino T, De Blasi A, Frati L, et al. (2006) The platelet maximum number of A2A receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 393: 27–30.  
7. Deckel AW, Gordinier A, Nuttal D, Tang V, Kusuda C, et al. (2001) Reduced activity and protein expression of NOs in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res 919: 70–81.  
8. Puca AA, Carrizzo A, Ferrario A, Villa F, Vecchione C (2012) Endothelial nitric oxide synthase, vascular integrity and human exceptional longevity. Immune Ageing 9: 26.  
9. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. European Heart Journal 33: 829–837, 837a–837d.  
10. Mount PF, Kemp BE, Power DA (2007) Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271–279.  
11. Calabrese V, Bates TE, Stella AM (2000) NO synthase and NO-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation. Brain Res 951: 36–42.  
12. Dukart J, Schroeter ML, Mueller K (2011) Age correction in dementia—matching to a healthy brain. PLoS One 6: e22193.  
13. (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11: 136–142.  
14. Marler K, Sandler S, Lechich A, Klager J, Albert SM (2002) Relationship between CAG repeat length and late-stage outcomes in Huntington’s disease. Neurology 59: 1622–1624.  
15. (1991) Declaration of Helsinki. Law Med Health Care 19: 264–265.  
16. Gentile MT, Vecchione C, Marino G, Arelini A, Di Pardo A, et al. (2008) Resistin impairs insulin-evoked vasodilation. Diabetes 57: 577–583.  
17. (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11: 136–142.  
18. Marler K, Sandler S, Lechich A, Klager J, Albert SM (2002) Relationship between CAG repeat length and late-stage outcomes in Huntington’s disease. Neurology 59: 1622–1624.  
19. Vecchione C, Brandes RP (2002) Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91: 173–179.  
20. Carrizzo A, Puca A, Damato A, Marino M, Franco E, et al. (2013) Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 62: 359–366.  
21. Kadomski M, Mocnaka S (1983) An improved method for washing of human platelets with prostacyclin. Thromb Res 30: 383–389.  
22. Ku CJ, Kuruzarathane W, Kenyon S, Root P, Spence D (2007) Fluorescence determination of nitric oxide production in stimulated and activated platelets. Anal Chim Acta 79: 2421–2426.  
23. Squini F, Maglione V, Orobello S, Formai F (2011) Genotype-, aging- dependent abnormal caspase activity in Huntington disease blood cells. J Neuroimmunol 218: 1599–1607.  
24. Runne H, Kuhn A, Wild EF, Pratyalshka W, Kristiansen M, et al. (2007) Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood. Proc Natl Acad Sci U S A 104: 14424–14429.  
25. Markianos M, Panas M, Kallikakis N, Vassilopoulos D (2004) Platelet monoamine oxidase activity in subjects tested for Huntington’s disease gene mutation. J Neuroimmunol 111: 475–483.  
26. Muramatsu Y, Kaizu H, Imai H, Nozaki M, Fujimura H, et al. (1982) Abnormal platelet aggregatory response in Huntington’s disease. Arch Psychiatr Nervenkund 232: 191–200.  
27. Deckel AW, Tang V, Nuttal D, Gary K, Elder R (2002) Altered neuronal nitric oxide synthase expression correlates with disease progression in Huntington’s disease transgenic mice. Brain Res 939: 76–86.  
28. Deckel AW (2001) Nitric oxide and nitric oxide synthase in Huntington’s disease. J Neurosci Res 69: 99–107.  
29. Lenczalo J (2001) Nitric oxide sufficiency, platelet activation, and arterial thrombosis. Circ Res 89: 766–762.  
30. Pirazzoli M, Jennings NL, Davern P, Lambert G, Su YD, et al. (2012) Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington’s disease. Journal of Physiology-London 590: 5845–5860.  
31. Mihm MJ, Amann DM, Schanscher BL, Atschohl RA, Bauer JA, et al. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis 25: 297–308.  
32. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, et al. (1997) Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 30: 817–824.  
33. Fulton D, Grattan JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597–601.  
34. Reynolds NC Jr, Hellman RS, Tikofsky RS, Prost RW, Mark LP, et al. (2002) Single photon emission computed tomography (SPECT) in detecting neurodegeneration in Huntington’s disease. Nucl Med Commun 23: 13–18.